POLICY NAME Joenja (leniolisib) POLICY # 3204P

Criteria

Coverage Criteria	
	Diagnosis of activated phosphoinositide 3-kinase (PI3K) delta syndrome (APDS)
	 Diagnosis must be confirmed by gene testing to support APDS mutation variant in either
	PIK3CD or PIK3R1 genes
	Documentation of clinical symptoms are consistent with APDS such as recurrent lung infections,
	enlarged lymph nodes, enlarged spleen, autoimmune low levels of blood cells and/or lung or
	liver dysfunction
	Documentation of at least one measurable nodal lesion on a computerized tomography (CT) or
	magnetic resonance imaging (MRI) scan
	Age 12-75 years
	Age 12-73 years
	Prescribed by or in consultation with an immunologist (immune system doctor) or other
	specialist
	Documentation to support previous trial and failure or contraindication to standard of care (such
	as antibiotics, immunoglobulin therapy, immunosuppressants (such as sirolimus)
	Clinical review of documentation confirming that patient has met all of the above requirements
	for treatment completed by both a pharmacist and medical director
Exclusion Criteria – Any of the following prevents coverage	
	Pregnancy
	Moderate to severe liver impairment